INTRODUCTION
In smooth muscle, contraction is initiated by Ca2+-dependent phosphorylation of the regulatory light chain of myosin. Myosin light-chain kinase (MLCK) is the Ca2+/calmodulin-dependent enzyme which catalyses the phosphorylation of myosin light chain, and is therefore the key regulatory protein in smoothmuscle contraction Sellers and Adelstein, 1987) . The complete amino acid sequences of MLCK were determined from both skeletal muscle (Takio et al., 1986; Roush et al., 1988; Leachman et al., 1989; Herring et al., 1990a) and smooth muscle (Olson et al., 1990; Gallagher et al., 1991) , and it is known that the molecules are quite distinct. For smoothmuscle MLCK, the sequence conserved among various protein kinases is found in the central portion of the molecule, suggesting it to be a catalytic domain. The regulatory domain resides at the C-terminal side of the catalytic core and consists of the autoinhibitory region and calmodulin-binding region (Olson et al., 1990; Gallagher et al., 1991) . The calmodulin-binding region was identified by isolating the calmodulin-binding peptide (Lukas et al., 1986) and later by truncation of the recombinant MLCK (Bagchi et al., 1989) . The structure required for calmodulin binding was recently revealed by analysing the three-dimensional structure of the peptide-calmodulin complex by multidimensional n.m.r. spectroscopy (Ikura et al., 1992) , and it was found that two hydrophobic residues, ten amino acid residues apart, play an essential role for the binding to calmodulin. On the other hand, it has been shown that the autoinhibitory region exists at the N-terminal side of the calmodulin-binding region. This was suggested by use of synthetic peptide analogues that modelled the N-terminal side of the calmodulin-binding region of MLCK. The peptides showed potent inhibitory activity against native MLCK as well as unregulated MLCK (Ikebe et al., 1987; Ikebe, 1990; Pearson et al., 1991) . It was also demonstrated (Ikebe et al., 1987) that the proteolysis of smoothmuscle MLCK yields a 64 kDa inactive fragment which is further protected by calmodulin binding. The results also suggest that the ATP-binding site is accessible to the nucleotide substrate regardless of calmodulin binding. The FSBA-labelled MLCK was completely proteolysed by a-chymotrypsin, and the '4C-labelled peptides were isolated and sequenced. The sequence of the labelled peptide was Ala-Gly-X-Phe, where X is the labelled residue. The sequence was compared with the known MLCK sequence, and the labelled residue was identified as lysine-548, which is located downstream of the GXGXXG motif conserved among ATP-utilizing enzymes.
proteolysed to produce a 61 kDa active Ca2+/calmodulinindependent kinase. The cleavage sites that produce the inactive fragment, i.e. 64 kDa fragment and the constitutively active MLCK, were identified to be on the N-terminal side of the calmodulin-binding region (Pearson et al., 1988; Ikebe et al., 1989) .
The mechanism by which the regulatory region controls the kinase activity is still obscure. Kemp et al. (1987) proposed that the autoinhibitory region serves as a pseudo-substrate inhibitor because of the similarity between the autoinhibitory region and the sequence ofmyosin light-chain N-terminus to the phosphorylation site. Although this is an attractive model to explain the regulatory mechanism, the replacement of basic amino acid residues in the autoinhibitory region with acidic residues, which is the key requirement of the pseudo-substrate inhibitor hypothesis, did not produce the constitutively active enzyme (Herring, 1991) . We also observed that deletion of the Arg-ArgLys motif, essential for the pseudo-substrate inhibitor hypothesis, did not disrupt the inhibited form of smooth-muscle MLCK (K. Yano and M. Ikebe, unpublished work), suggesting that the inhibition does not arise from pseudo-substrate inhibition.
It is reasonable, however, to assume that the regulatory region of MLCK interacts with the catalytic domain in order to modulate the enzyme activity. In this respect, it is important to understand the structure of the active site and possible modulation of the active-site conformation due to interaction with the regulatory sites. In the present study, we employed 5'-[p-(fluorosulphonyl)benzoyl]adenosine (FSBA) as a probe to study the ATP-binding-site structure. FSBA is an ATP analogue which has been shown to be an effective affinity-labelling reagent which covalently modifies the nucleotide-binding site ofenzymes (Zoller et al., 1981; Kamps et al., 1984; Russo et al., 1985) . The compound consists of an adenosine moiety which binds to ATPbinding sites and a fluorobenzoyl moiety which reacts with amino acid residues at the fluorosulphonyl position (Figure 1 
MATERIALS AND METHODS
Proteins were prepared by the following procedures: MLCK from frozen turkey gizzards (Ikebe et al., 1987) ; calmodulin from bull testes ; 20 kDa light chain from gizzard myosin (Hathaway and Haeberle, 1983; Ikebe et al., 1988 The [4C]FSBA-labelled protein was digested by a-chymotrypsin (1:440, w/w) at 25°C for 16 h. The digest was loaded on a TSK DEAE 5 PW column (7.5 mm x 750 mm) (Tosoh, Tokyo, Japan) attached to a Perkin-Elmer h.p.l.c. system which was equilibrated with 0.01 M NH4HCO. The peptides were eluted with a linear NH4HCO3 gradient. The fractions (0.6 ml/tube) were collected at a flow rate of 0.6 ml/min. A portion (120 ,1 of a-chymotrypsin-treated MLCK reacted with FSBA in the presence of MgATP, or 60 F1 of a-chymotrypsin-treated MLCK reacted with FSBA in the absence of MgATP) of each fraction was mixed with 5 ml ofscintillation cocktail, and the radioactivity ofeach fraction was measured in a Beckman LS 3801 scintillation counter. The radioactive fractions were pooled, freeze-dried and applied to a Spheri-5 RP-18 (Brownlee Labs) C18 reverse-phase column attached to the h.p.l.c. system. The peptides were eluted with a linear CH3CN gradient in 0.1 % trifluoroacetic acid. Fractions (0.8 ml/tube) were collected at a flow rate of 0.8 ml/min, and a portion (300 ,ul) of each fraction was taken to measure the radioactivity as described above. Amino acid sequences of the radioactive peptides were determined on an Applied Biosystem 477A protein sequencer.
Protein concentrations were determined by the method of Bradford (1976) or by spectrophotomeric measurements for MLCK (A]L% = 11.4) (Adelstein and Klee, 1981) , calmodulin (Al%A/ = 1.9) (Watterson et al., 1976) , and the 20 kDa light chain (Al% = 3.37) (Hathaway and Haeberle, 1983 (Colburn et al., 1987) and recently for smooth-muscle MLCK (Kennelly et al., 1992) .
Protection against the inactivation of MLCK by FSBA was examined in the presence ofvarious nucleotides (Table 1) . MLCK was better protected against inactivation in the presence of The above results showed that FSBA modified residues important for MLCK activity, and we therefore attempted to identify the FSBA-labelled residues. To accomplish this, we synthesized FSBA in which '4C is incorporated in the benzoyl moiety (Colburn et al., 1987) , since the commercially available radioactive FSBA (New England Nuclear) contains 14C in the adenine ring, which would be lost from the peptide by hydrolysis at the ester bond under the acidic conditions used for purification of the affinity-labelled peptides. The affinity labelling of smoothmuscle MLCK with 14C-labelled FSBA was performed under the following three conditions: (I) methods section, and the labelled MLCK was digested with achymotrypsin, and then the digests were subjected to DEAE 5 PW anion-exchange chromatography (Figure 3) . Four radioAla-Gly-X-Phe Ala-Gly-X-Phe Ala-Gly-X-Phe Ala-Gly-X-Phe Ala-Gly-X-Phe Ala-Gly-X-Phe * Peptide obtained from MLCK labelled in the absence of Ca2+/calmodulin. t Peptides obtained from MLCK labelled in the presence of Ca2+/calmodulin. active peaks were observed. Among them, peak ID was found to be large peptide fragments of MLCK which were not completely digested by a-chymotrypsin, as judged by SDS/PAGE. Therefore, peak ID was not further analysed. The other three radioactive peaks were observed in all three conditions. The radioactive fractions were pooled, and subjected to C18 reverse-phase chromatography (Figure 4) .
From fraction A from the labelling conditions I, two radioactive peaks, IAI and IA2, were obtained (Figure 4a ). The two radioactive peaks, IBI and IB2, were also obtained from fraction B from the labelling condition I (Figure 4b) . From fraction C, a single radioactive peak was obtained (Figure 4c ). These purified radio-labelled peptides were subjected to sequence analysis. The sequences of all five peptides were identified as Ala-Gly-X-Phe (Table 2) , in which X is the FSBA-labelled residue, although the elution positions of these peptides were distinct. The reason for the difference in the elution position for these five fractions during chromatography is unclear, but possibly it may arise from additional reactions involving the benzoyl group after hydrolysis during isolation of the peptide, arising as a consequence of the difference in the bound moieties of FSBA to the amino acid residue. To support this, it was found that the elution positions of amino acid phenylthiohydantoins of the labelled residues (X) in the peptides were distinct from one another (results not shown). The radioactive peptides which were labelled with FSBA in condition II were also purified, and five radioactive peptides were obtained. The elution positions of these peptides were nearly identical with those of the peptides labelled in condition I (results not shown), suggesting that the peptides obtained in labelling condition II are the same as those obtained in labelling condition I (Figure 4) . Actually the sequence of peptide IIB2 was found to be Ala-Gly-X-Phe (Table 2) . When MLCK was labelled with FSBA in the presence of excess ATP, the amount of radioisotope incorporated in the corresponding labelled peptides, i.e. IIIAI, IIIBI and IIIB2, was markedly decreased (only onefifth to one-tenth of radioisotope was incorporated into the peptides) (results not shown). Peaks A2 and Cl were not detected in this condition. These results clearly show that the labelling of the X residue in the peptide Ala-Gly-X-Phe is ATP-sensitive. Although ATP-sensitive labelling of MLCK by FSBA was abolished by adding excess ATP, MLCK activity was decreased slowly even in the presence of ATP (Figure 2 ). However, we could not find any particular radiolabelled peptides derived from ATP-insensitive labelling (results not shown). It has been shown (Togashi and Reisler, 1982) that FSBA modifies cysteine residues to form thiosulphonate, which is followed by displacement of FSBA by another cysteine residue to yield a disulphide. This process may be responsible for the ATP-insensitive inactivation of MLCK by FSBA. The location of the labelled peptide was The numbering of amino acid residues and domain structure of MLCK were referenced with the amino acid sequence data reduced from a full-length cDNA (Olson et al., 1990 ). The putative substratebinding site was referenced with reports of skeletal-muscle MLCK by Herring et al. (1990a,b The ATP-binding site of smooth-muscle MLCK (smMLCK) (Olson et al., 1990 ) was compared with the following sequences of the ATP-binding site of protein kinases: unc-22 (Benian et al., 1989) ; skeletal-muscle MLCK (skMLCK) (Herring et al., 1990a) ; Ca2+/calmodulin-dependent protein kinase type 11 (CaMII-cz) (Lin et al., 1987) ; phosphorylase kinase y subunit (PhK-y) (Reimann et al., 1984) ; cyclic-AMP-dependent protein kinase catalytic subunit, a-form (cAPK-x) (Shoji et al., 1983) ; protein kinase C, a form (PKC-az) (Parker et al., 1986) , and epidermal-growth-factor receptor (EGFR) (Ulirich et al., 1984) . For each position, residues found in at least four copies are shaded. Numbers in parentheses indicate positions in amino acid sequences of the protein kinases. Alignment and consensus sequence were referenced with a review by Hanks et al. (1988) .
assigned according to the complete amino acid sequence (Olson et al., 1990) , and it was found that the residue labelled with FSBA was lysine-548 ( Figure 5 ). This is located downstream of the GXGXXG motif which is conserved among ATP-utilizing enzymes and is thought to be a part of the ATP-binding pocket ( Figure 5 ). The acidic-residue-rich sequence, corresponding to the putative substrate (light chain)-binding region proposed by Herring et al. (1990a,b) in skeletal-muscle MLCK, is positioned upstream of this lysine residue. This lysine residue is conserved among various protein kinases (Figure 6 ), and it was previously shown that FSBA labelled this consensus lysine residue of cyclic-AMP-dependent protein kinase (Zoller et al., 1981) , V-src (Kamps et al., 1984) and epidermal-growth-factor receptor kinase (Russo et al., 1985) . Recently, the three-dimensional structure of the catalytic subunit of cyclic-AMP-dependent protein kinase was determined by X-ray crystallography (Knighton et al., 1991) . Since all known protein kinases share a conserved catalytic core homologous to the catalytic subunit ofcyclic-AMP-dependent protein kinase, the catalytic core of MLCK was modelled according to the structure of the cyclic-AMP-dependent protein kinase (Knighton et al., 1992) . According to the model, lysine-548 is on fl-sheet 3 in the small lobe which serves as the binding site for MgATP.
